Latest

• Evidence that innovative medicines improve health and economic outcomes: focused literature review.

  There is abundant empirical evidence that pharmaceutical innovation improves population-level health outcomes and societal-level net economic benefits. »

• Close the Gaps: Patient Benefits and Taxpayer Costs of 3 Pharmacare Options.

  Study weighs the options being considered by the federal Advisory Council on the Implementation of National Pharmacare. »

• Pan-Canadian Pharmaceutical Alliance negotiations 2014-2018.

  The pCPA should demonstrate to Canadians that its negotiations to contain the costs of new drugs are not limiting patients’ access to innovative drugs. »

• Facts about the cost of patented drugs in Canada: 2018 Edition.

  Policymakers are not fully informed about pharmaceutical costs - particularly regarding patented medicines. »

• Out-of-pocket prescription drug costs: What are the implications for National Pharmacare?

  National Pharmacare advocates claim that out-of-pocket costs for prescription drugs are forcing people to trade-off food, heat and rent versus medicines. Is it true? »

• New Patented Medicine Regulations in Canada: Case Study of a Manufacturer’s Decision-Making

  This case study demonstrates that the proposed changes in the PMPRB’s guidelines will create a high level of uncertainty among manufacturers of drugs for rare disorders. »

• Taxpayer Cost of National Pharmacare: Disputing the Parliamentary Budget Officer’s Estimate

  Study suggests PBO underestimated the cost of National Pharmacare; adjusting the gaps in existing public drug plans would be less expensive for taxpayers. »

• Coverage of new medicines in Federal-Provincial public drug plans in Canada 2008-2017

  Public drug plan coverage is low, slow and inconsistent: bad news for patients, Pharmacare and pCPA. »

• Coverage of new medicines in public versus private drug plans in Canada 2008-2017

  Experience forewarns that National Pharmacare will reduce access to medicines. »